MOUNJARO SOLUTION

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Kauptu það núna

Download Vara einkenni (SPC)
23-11-2022

Virkt innihaldsefni:

TIRZEPATIDE

Fáanlegur frá:

ELI LILLY CANADA INC

ATC númer:

A10BX16

INN (Alþjóðlegt nafn):

TIRZEPATIDE

Skammtar:

2.5MG

Lyfjaform:

SOLUTION

Samsetning:

TIRZEPATIDE 2.5MG

Stjórnsýsluleið:

SUBCUTANEOUS

Einingar í pakka:

100

Gerð lyfseðils:

Prescription

Vörulýsing:

Active ingredient group (AIG) number: 0164301001; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2022-11-24

Vara einkenni

                                _ _
_MOUNJARO (tirzepatide injection) _
_Page 1 of 45_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MOUNJARO™
tirzepatide injection
Solution, 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL,
12.5 mg/0.5 mL,
15 mg/0.5 mL, in a single-dose prefilled pen for subcutaneous use
Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like
Peptide-1 (GLP-1)
Receptor Agonist
Antihyperglycemic Agent
Eli Lilly Canada Inc.
Exchange Tower
130 King Street West, Suite 900
P.O. Box 73
Toronto, Ontario
M5X 1B1
1-888-545-5972
www.lilly.ca
Date of Initial Authorization:
NOV 23, 2022
Submission Control Number: 259103
MOUNJARO is a trademark owned by or licensed to Eli Lilly and Company,
its subsidiaries or
affiliates.
_ _
_MOUNJARO (tirzepatide injection) _
_Page 2 of 45_
RECENT MAJOR LABEL CHANGES
None at time of authorization
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.....................................................................................
2
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
4
1
INDICATIONS..............................................................................................................
4
1.1
Pediatrics
...........................................................................................................
4
1.2
Geriatrics............................................................................................................
4
2
CONTRAINDICATIONS
...............................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS
BOX...................................................... 5
4
DOSAGE AND ADMINISTRATION
..............................................................................
5
4.1
Dosing Considerations
...........
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Vara einkenni Vara einkenni franska 23-11-2022

Leitaðu viðvaranir sem tengjast þessari vöru